Sarah Cannon Research Institute Partners with BostonGene to integrate molecular testing and informatics platforms

Sarah Cannon Research Institute shared a post by BostonGene on LinkedIn, adding:

“We are excited to announce our partnership with BostonGene to integrate their molecular testing and informatics platforms into our network. This collaboration is set to validate novel biomarkers using BostonGene’s AI-powered multiomics platform in real-world cancer populations, enhancing our personalized oncology care.
Learn more.”

Quoting BostonGene:

“We are excited to collaborate with Sarah Cannon Research Institute (SCRI) to integrate innovative molecular testing and informatics platforms into the clinical decision-making processes at SCRI’s Phase 1 clinics. This collaboration also aims to validate novel biomarkers using BostonGene’s AI-powered multiomics platform in real-world cancer populations, further advancing the potential for personalized oncology care.

“By integrating BostonGene’s advanced molecular profiling into our phase 1 clinical workflows, physicians are poised to significantly enhance our ability to make precise, data-driven treatment decisions. We look forward to the impact we can make in advancing personalized oncology care through our strategic collaboration. ” – Andrew McKenzie, PhD, Vice President of Personalized Medicine at SCRI and Scientific Director at Genospace.

“We are thrilled to collaborate with SCRI, integrating our AI-driven multi-omics platform into select community oncology practices. This collaboration will enable us to personalize cancer treatment more effectively and expedite biomarker discovery and validation, ultimately shifting the standard of care and improving patient outcomes.” – Nathan Fowler, MD, Chief Medical Officer at BostonGene.”

Read more.